Clinical Trial Update: Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase II trial evaluating the safety and efficacy of inhaled alpha-1 antitrypsin in cystic fibrosis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• inhaled alpha-1 antitrypsin (alpha-1 antitrypsin)

Snippet

Sponsor: Kamada, Ltd. | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED